6CM
NAUT icon

683 Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

683 Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-267,454
Closed -$2.7M – 219
2021
Q2 		$2.7M Hold
267,454
– – 0.09% 109
2021
Q1 		$3.69M Sell
267,454
-132,546
-33% -$1.84M 0.2% 80
2020
Q4 		$4.34M Hold
400,000
– – 0.21% 74
2020
Q3 		$4.33M Buy
+400,000
New +$4.27M 0.32% 56

Other funds holding NAUT

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

683 Capital Management's NAUT Position: Q3 2021 in Review

683 Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q3 2021, closing a stake of 267,454 shares — an estimated $2.7M sold.

683 Capital Management first reported a position in NAUT in Q3 2020 and held it in 4 quarters. The position peaked at $4.34M in Q4 2020. 72 funds tracked by Wall St. Rank hold NAUT as of Q3 2021.

  • 683 Capital Management reported no remaining Nautilus Biotechnolgy position as of Q3 2021 after selling out during the quarter.
  • 683 Capital Management sold 267,454 Nautilus Biotechnolgy shares in Q3 2021, an estimated $2.7M.
  • 683 Capital Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 4 quarters.
  • 683 Capital Management's Nautilus Biotechnolgy position peaked at $4.34M in Q4 2020.
  • 72 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2021.

Based on 683 Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.